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Abstract Monocytes as well as lymphocytes infiltrate in the 
stroma of thyroid tissue in autoimmune and destructive 
thyroiditis. Monocyte chemoattractant protein-1 (MCP-I) is a 
cytokine that attracts T-lymphocytes as well as monocytes. 
Using human thyrocytes in primary cultures, we show that 
expression of MCP-1 mRNA and protein is remarkably 
stimulated by both interleukin-1 (IL-1) and tumor necrosis 
factor-~ (TNF-ct), and also that interferon- T (IFN-~/) by itself is a 
weak stimulant but has a synergistic activity with either IL-1 or 
TNF-c¢, The finding indicates that MCP-1 can be produced by 
thyrocytes themselves, uggesting a possible role of thyrocytes on 
accumulation of monocytes and T-lymphocytes to the tissue from 
the blood in autoimmune and destructive thyroiditis. 
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1. Introduction 
The chemokines form a superfamily of small (8-10 kDa), 
inducible, secreted chemotactic cytokines (for reviews see [1- 
5]). Chemokines such as interleukin-8 (IL-8) that attract 
mainly neutrophils are mostly members of the ~ subfamily, 
whereas those such as MCP-1 that attract mainly monocytes 
belong to the 13 subfamily [1 5]. Although MCP-I is originally 
reported to be an attractant for monocytes but not for neu- 
trophils or lymphocytes [6], the cytokine has recently been 
shown to chemoattract T-lymphocytes in addition to mono- 
cytes [7,8]. Based on its in vitro and in vivo functions, the 
correlation of MCP-I expression and the pathologies or 
pathophysiologies have already been studied in several dis- 
eases and are still under investigation in a wide variety of 
immune and inflammatory diseases [1-5,9-14]. 
The thyroid gland is a main target for autoimmune attack 
in humans (for a review, see Refs. [15,16]). Hashimoto's thyr- 
oiditis and Graves' disease are both autoimmune thyroid dis- 
eases. Analysis of the intrathyroidal production of cytokines 
in such disease has revealed the expression of IFN-y, TNF-c~ 
and 1], IL-2, IL-6, IL-8 and IL-10 [17,18]. In addition, human 
thytocytes themselves have been reported to produce IL-1, IL- 
6, IL-8 and TGF-I~ [17-19], although the expression of IL-1 is 
controversial [18]. Subacute thyroiditis is a relatively acute 
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disease of inflammation possibly caused by certain viral infec- 
tion [20], and painless thyroiditis is caused by an acute exacer- 
bation of an autoimmune process related to Hashimoto's 
thyroiditis [20]. Both diseases are known as destructive thy- 
roiditis. Macrophages and lymphocytes are prominent in the 
infiltrates of destructive thyroiditis as well as autoimmune 
thyroiditis, and macrophages and dendritic cells can present 
thyroid antigen to T-lymphocytes in vitro [21]. Thus, cyto- 
kines produced by infiltrated mononuclear cells and by thy- 
rocytes themselves play a central role in thyroid autoimmune 
and inflammatory responses. The initiation of infiltration and 
further recruitment of mononuclear cells into thyroid stroma, 
an important step to induce immune and inflammatory re- 
sponses, should be mediated by some chemoattractant pro- 
teins. IL-8 produced by thyrocytes has already been suggested 
to have a possible role at least in part in accumulation of T- 
lymphocytes within the gland in autoimmune thyroid disease 
[18,19], because IL-8 was shown to attract T-lymphocytes [22] 
in addition to neutrophils [23,24]. However, IL-8 is not a 
chemoattractant for monocytes and the effect of IL-8 on lym- 
phocytes is still questionable [5]. Thus, it is very important o 
know whether MCP-1 may be produced by human thyrocytes. 
2. Materials and methods 
2.1. Materials 
Recombinant human (rh) IL-lot (2× 10 z U/mg protein) was gener- 
ously supplied by Otsuka Pharmaceuticals Co., Tokushima, Japan. 
rhlFN-y was supplied by Shionogi Pharmaceuticals Co., Osaka, Ja- 
pan. rhTNF-c~ (3.5 × 10 7 U/mg protein) was purchased from Funa- 
koshi, Tokyo, Japan. Human MCP-I enzyme immunoassay (EIA) kits 
were purchased from R&D systems, Inc., MN. 
Human thyroglobulin (TG) radioimmunoassay (RIA) kits were ob- 
tained from Daiichi RI Lab., Tokyo, Japan. All other chemicals were 
purchased from Sigma Chemicals Co., St. Louis, MO. 
2.2. Cell culture 
We obtained two specimens of thyroid tissues resected from two 
Graves' patients. Each specimen was digested with collagenase as 
reported elsewhere [25]. Cells (open thyroid follicles) in Ham F-12 
medium supplemented with 10% heat-inactivated f tal bovine serum 
(FBS) were seeded into 48-well plates (0.2 ml/well), 60-mm dishes (2 
ml/dish) or 100-mm dishes (8 ml/dish) and cultured with 5% CO2 in 
humidified atmosphere at37 ° C. Cells were used for experiment after 
confluence and the contamination f fibroblast was less than 5%. 
2.3. Assay of human MCP-1 and human thyroglobulin (TG) in culture 
supernatant 
Assay of MCP-1 in the culture supernatant of human thyrocytes 
was performed using human MCP-1 EIA kits according to manufac- 
turer's recommendation. Both the immobilized (coated) monoclonal 
antibody and enzyme-linked polyclonal antibody raised against 
rhMCP-1 are specific for human MCP-1 and do not cross-react 
with 12 factors related to or associated with MCP-I, including 
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rhMCP-2, rhMCP-3 and rhlL-8, and also with 86 cytokines, including 
rhIL-lc~, rhIL-l[3, rhTNF-c~, rhIFN-7 and various recombinant hu- 
man cytokine soluble receptors. Assay of TG was performed by RIA. 
2.4. Analysis of mRNA levels Jor MCP-I by RT-PCR 
RNA was extracted from thyrocytes in a 60-mm or 100-mm dish 
using a modified guanidinium isothiocyanate method (RNAzol; Cin- 
na/Biotex, Houston, TX). RT-PCR was performed using standard 
methods. Briefly, the first strand cDNA was synthesized using random 
primers and M-MLV reverse transcriptase (Promega, Madison, WI), 
followed by PCR amplification using synthetic gene primers specific 
for human MCP-I deduced from the cDNA sequences reported pre- 
viously [26], and for human thyroglobulin (TG) and human glycer- 
aldehyde-3-phosphate dehydrogenase (GAPDH) as reported pre- 
viously [25]. Primers used were: MCP-1 forward 25-mer, 5'- 
TCGCTCAGCCAGATGCAATCAATGC-3': MCP-I reverse 24-mer, 
5'-CCCAGGGGTAGAACTGTGGTTCAA-3'; TG forward 21-mer, 
5'-CTGCGGAGGGAGAGTTTATGC-3'; TG reverse 21-mer, 5'- 
AGGTCGTGCTGGCTGAAGTAG-3'; GAPDH forward 26-mer, 5'- 
TGAAGGTCGGAGTCAACGGATTTGGT-3'; GAPDH reverse 24- 
mer, 5'-CATGTGGGCCATGAGGTCCACCAC-3'. PCR amplifica- 
tion was performed for 30 cycles using a DNA PCR kit (Perkin Elmer 
Cetus, Norwalk, CT) as reported previously [25]. PCR products were 
electrophoresed on a 1.5% agarose gel containing ethidium bromide 
and visualized by UV-induced fluorescence. PCR reactions resulted in 
the amplification of a single product of the predicted size for MCP-I 
(479 bp) and TG (613 bp) [data not shown]. 
2.5. Statistical analysis 
Values are expressed as a mean+standard deviation (S.D.) of 3 
wells or a mean of 2 dishes. Statistical analysis was performed by 
unpaired t-test and two-way analysis of variance (ANOVA). A P- 
value less than 0.05 was considered significant. 
3. Results 
Unstimulated thyrocytes gradually secreted small amounts 
of MCP-1 during a 24-h incubation. Thyroid stimulating hor- 
mone (TSH; 20 mU/ml) did not increase but appeared to 
inhibit slightly the amounts of MCP-1 secreted by the cells. 
IL-1 (20 ng/ml) remarkably stimulated MCP-1 secretion by 
over 10-fold. IFN-,/ (100 U/ml) potentiated IL- l- induced 
MCP-1 secretion throughout the period (Fig. 1A). TSH 
clearly stimulated the expression of TG, a thyroid-specific 
protein, mRNA after a 24-h incubation, but IL-I with or 
without IFN-, /blocked this TSH-induced TG mRNA expres- 
sion, The secretion of TG induced by TSH was higher by 
about 5-fold after a 48-h incubation when compared with 
that in basal condition. TSH-induced secretion of TG was 
again completely blocked by IL-1 in the presence or absence 
of IFN-7 (Fig. 1B). Next, we studied the time course changes 
of MCP-1 mRNA expression in IL-l-stimulated thyrocytes. 
An increase in abundance in MCP-1 mRNA became evident 
as early as 1 h after IL-1 (20 ng/ml) stimulation when com- 
pared with the basal level, peaked at 2-4 h and then declined 
gradually to 24 h (Fig. 2A). TNF-a  (20 ng/ml) also strongly 
stimulated MCP-1 gene expression as similarly as IL-1, 
whereas IFN-  7 (100 U/ml) only slightly did so (Fig. 2B). As 
shown in Fig. 3A,B, both IL-1 and TNF-c~ dose-dependently 
stimulated MCP-1 production by the cells during a 48-h in- 
cubation. IFN-y (100 U/ml) by itself slightly stimulated its 
production but exhibited a synergistic activity with either 
IL-1 or TNF-~. 
Actinomycin D (1 gg/ml) almost completely inhibited the 
expression MCP-I  mRNA and protein in both IL-l-stimu- 
lated and unstimulated cells. Cycloheximide (10 gg/ml) also 
inhibited MCP-1 secretion while the gene expression was 
clearly augmented in basal condition but slightly inhibited in 
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Fig. ]. Time course changes in the amounts of  MCP- I  in the cul- 
ture supernatant of human thyrocytes (A), and changes in the 
amounts of TG and the expression of MCP-I and TG mRNAs in 
the cells (B). Human thyrocytes were incubated in the medium alone 
(basal), or in the medium supplemented with TSH (20 mU/ml), 
TSH+IL-1 (20 ng/ml) or TSH+IL-I/IFN- 7 (20 ng/ml+ 100 U/ml). 
At the indicated times, MCP-I secreted in the culture supernatant 
was measured and expression of mRNAs for TG and MCP-1 was 
analyzed in the cells cultured in 100 mm-dish. After 48 h incuba- 
tion, TG secreted by the cells in the culture supernatant of 48-well 
plate was measured. The data represented are a mean value of two 
dishes or a mean value + S.D. of three wells. 
IL-l-stirnulated condition. Dexamethasone attenuated the ex- 
pression of MCP-1 mRNA and protein in both conditions 
(Fig. 4). Thyrocytes obtained from two Graves' tissues re- 
sponded well to such proinflammatory cytokines and charac- 
teristic of the responses was very similar in each of these 
thyrocytes. 
4. Discussion 
The expression of MCP-1 mRNA and protein in human 
thyrocytes was strongly up-regulated by either IL-1 or TNF-  
c~ and IFN-7 potentiated IL-I-  or TNF-~-induced MCP-1 
expression. TSH was rather inhibitory on the cytokine(s)-in- 
duced MCP-1 expression. In contrast, the expression of TG, a 
thyroid-specific protein, mRNA and protein was remarkably 
stimulated by TSH and this TSH-dependent up-regulation of 
TG expression was completely blocked by a co-administration 
of IL-I as reported previously [27]. Furthermore, over 95% of 
the cultured cells incubated with TSH alone were positively 
stained with anti-TG antibody (data not shown). These find- 
ings indicate that human thyrocytes themselves can produce 
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Fig. 2. Changes in mRNA levels for MCP-1 in human thyrocytes. 
Time course changes in the abundance of MCP-I mRNA in IL-I- 
stimulated thyrocytes (A). Expression of MCP-1 mRNA in thyro- 
cytes 4 h after stimulation of IL-I, TNF-c~ or IFN-y (B). Thyrocytes 
were cultured in 60-mm dish in 2 ml of Ham F-12 medium contain- 
ing 10% FBS. RNA was extracted at the indicated times after IL-1 
(20 ng/ml) stimulation or 4 h after stimulation with varying doses 
of IL-I (0.2-20 ng/ml), TNF-o~ (20 ng/ml) or IFN-y (100 U/ml). The 
abundance of mRNAs for MCP-1 and GAPDH as reference was 
evaluated by RT-PCR. 
MCP-1, suggesting a possible role of thyrocytes to participate 
in the recruitment of monocytes and T-lymphocytes from the 
blood stream into thyroid stroma through MCP-1 production. 
Activated monocytes/macrophages secrete IL-1 and TNF, and 
activated lymphocytes produce IFN-y. These potent proin- 
flammatory cytokines are expressed in the tissues of autoim- 
mune thyroid disease [17,18], indicating that not only recruit- 
ment but also activation of mononuclear cells really takes 
place in vivo. This would constitute an amplification loop of 
the immune and inflammatory esponses through a paracrine 
way. This is also proposed to be the case in destructive thy- 
139 
roiditis, although direct evidence has been scarcely obtained 
because such thyroiditis hould not be surgically treated. 
Inhibition by actinomycin D of MCP-1 mRNA expression 
in both IL-l-stimulated and unstimulated cells, can be likely 
explained by transcriptional control of MCP-1 gene expres- 
sion. Since the mRNA for MCP-1 contains AUUUA se- 
quences in their 3' untranslated region which are typical for 
immediate early genes and cause instability of mRNA [28], the 
cycloheximide-dependent MCP-1 mRNA expression in un- 
stimulated thyrocytes can be interpreted as stabilization of 
the message due to the reduced synthesis of RNAases as 
has been already shown in smooth muscle cells, endothelial 
cells and mesangial cells [29 31]. In contrast, a slight inhib- 
ition by cycloheximide of the IL-l-induced expression of 
MCP-1 mRNA suggests that action of IL-1 might be partly 
dependent on new protein synthesis in thyrocytes. Regulation 
of the gene expression by cycloheximide s ems to be cell-spe- 
cific, because in peripheral blood monocytes cycloheximide 
caused inhibition [29,30]. Dexamethasone, a potent immuno- 
suppressive agent, inhibited both the gene expression and pro- 
tein secretion by thyrocytes as has been shown in other cell 
types [32]. The inhibition of gene expression by glucocorti- 
coids is generally caused through an interaction with gluco- 
corticoid-responsive elements in the promoter regions of 
genes, a modulation of AP-1 DNA binding activity [33] or/ 
and through production of I~cB, an inhibitory molecule for 
nuclear factor kappa B (NF-nB) [34,35]. Accordingly, these 
mechanism(s) may probably operate in thyrocytes. 
The present study demonstrates that in cultured human 
thyrocytes, MCP-I production and gene expression are re- 
markably up-regulated by proinflammatory cytokines like 
IL-I and TNF-c~ in the presence or absence of IFN-,/. The 
production of MCP-1 besides IL-8 by human thyrocytes may 
play a role in the recruitment of monocytes and T-lympho- 
cytes at immune inflammatory sites in thyroid gland from the 
blood, thus providing a possible mechanism by which thyro- 
cytes themselves may participate in the processes of thyroid 
autoimmune and inflammatory disease. 
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Fig. 3. Effects of IL-1 or TNF-c¢ on the secretion of MCP-1 by thyrocytes in the presence or absence of IFN- 7. Thyrocytes in 48-well plate 
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Fig. 4. Effects of dexamethasone, actinomycin D and cycloheximide on the expression of MCP-I protein and mRNA in unstimulated or IL-I- 
stimulated thyrocytes. Thyrocytes in 48-well plate were incubated in the medium with or without dexamethasone (Dex; 0.1 10 /aM), actinomy- 
cin D (AD; 1 gg/ml) or cycloheximide (CH; 10 /ag/ml) in the presence or absence of 20 ng/ml IL-1 for 48 h. The data represented are a 
mean+S.D, of three wells, a: P<0.05 and b: P<0.01 vs the respective control value. Expression of MCP-I mRNA was analyzed in thyro- 
cytes cultured in 60-mm dish for 4 h in the medium with or without AD (1 /ag/ml), CH (10 /ag/ml) or Dex (10 /aM) in the presence or absence 
of 20 ng/ml IL-1. 
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